Clinical Trial Update: Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) [Phase 3]

View source ↗

Summary

The Phase 3 trial evaluating NRP104 in adults with Attention-Deficit/Hyperactivity Disorder has completed. The snippet does not report the trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• NRP104

Snippet

Sponsor: New River Pharmaceuticals | Conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity | Phase 3 | Status: COMPLETED